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Objective: To examine the prevalence and clinical manifestations of cutaneous leish-
maniasis (CL) in Iran.
Methods: This study was conducted in Iran between 2011 and 2013. Sampling, pre-
paring, developing, and ﬁxing of suspicious skin lesions were completed in healthcare
centers in 31 Iranian provinces as well as in the Academic Reference Laboratory and the
National Reference Laboratory. The information was then analyzed at the Ministry of
Health's Information Management Center of Contagious Diseases.
Results: Over a three-year period, the number of people identiﬁed with CL was 56546.
The highest incidence was reported in 2011 (27.5 per 100000). Wet CL accounted for
43.7% of cases while 43.3% resulted from sporotrichoid leishmaniasis. The results
showed that there was a higher incidence of CL due to Leishmania major (50.2%) than to
Leishmania tropica. The results of this study found that the highest incidence of CL had
happened respectively in Ilam, Fars and, Khorasan Razavi Provinces between 2011 and
2013.
Conclusions: Although the incidence of the disease is declining, CL is still a public
health concern and disease control protocols need to be established. Therefore, further
studies are needed to identify the vectors, reservoirs, and disease species as well as to
develop appropriate disease control strategies.1. Introduction
Cutaneous leishmaniasis (CL), caused by several Leishmania
species, is a complex disease with a wide spectrum of clinical
features [1]. This parasitic disease is one of the most common
zoonotic diseases and a major public health problem
worldwide. Leishmaniasis occurs in three forms: cutaneous
(oriental sore), visceral (kala-azar), and mucocutaneous [2].
Although leishmaniasis is endemic in over 88 countries, it
mostly occurs in tropical and subtropical areas [3]. Annually,about 700000–1300000 new cases [4] and 20000–30000
deaths occur worldwide. About 95% of CL cases occur in the
Americas, the Mediterranean Basin, the Middle East, and
Central Asia and over two-thirds of new cases occur in six
countries: Afghanistan, Algeria, Brazil, Colombia, the Islamic
Republic of Iran, and the Syrian Arab Republic.
CL is one of the most common endemic diseases in Iran [5]
and the second most frequently transmitted arthropod-borne
parasitic disease after malaria [2].
Although about 20000 CL cases are reported in Iran each
year, the actual number of cases is most likely four or ﬁve times
higher. CL is observed in both rural and urban areas and can
present as either wet or dry lesions. In Iran, the rural type is
prevalent in 15 provinces of Iran while the urban type is
affecting almost all of the country's urban areas [6].
Iranian researchers have conducted several epidemiologic
studies of leishmaniasis since 1941. For example, in 2007,
26493 cases of leishmaniasis were reported (a rate of 37 per
100000). In 2010, this number had decreased to 21211 (a rate
of 27 per 100000 people). More than 90% of the casesarticle under the CC BY-NC-ND license (http://
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17 provinces [6]. In addition, research has reported that the
incidence of CL is  5000 people. The trend for CL
indicates that the number of cases has increased from 20718
in 1994 to 21211 in 2010 (Figure 1). Several factors have
contributed to the spread of CL worldwide. For example, ur-
banization, migration, warfare, and environmental modiﬁca-
tion have resulted in the dispersion of the disease while
improved diagnosis and case notiﬁcation have resulted in
increased reporting. Outbreaks of CL have recently occurred
throughout Iran where there is a suitable environment for
breeding of the vector, propagation of the organism, and
transmission of the causative agent [7–9]. Furthermore,
leishmaniasis has caused considerable morbidity and
mortality in many countries including Iran [3,10] and has had
a considerable, global health impact [11].1994 1995 1996  1997 1998  1999   2000  2001 2002 2003  2004  2005  2006  2007 2008 2009 2010
30 000
25 000
20 000
15 000
10 000
5 000
0
Cases
Figure 1. CL trend of 1994–2010.
Sources of information: World Health Organization Consultative Meeting
on Cutaneous Leishmaniasis in EMRO countries, Geneva, April 30, 2007
to May 2, 2007.
Table 1
Annual incidence rate per 100000 population between 2011 and 2013.
Year Number of
patients
Total
population
Incidence rate per
100000
2011 20692 75150518 27.5
2012 18868 76125496 24.7
2013 16976 76941000 22.0
Table 2
Demographic characteristics of CL patients. n (%).
Characteristics Number of patients
Occupation Housewife 11723 (20.7)
Student 9662 (17.1)
Child 8890 (15.7)
Worker 4061 (7.2)
Farmer 1826 (3.2)
Travel history No 31227 (55.2)
Yes 20365 (36.0)This disease imposes an economic burden on families and
societies as well as countries, particularly developing coun-
tries [3]. For example, glucantime, a medicine to treat CL, is
expensive and requires frequent injections increasing the
economic burden at all levels. In addition, drug resistance
and side effects (e.g., arrhythmia, increased liver enzymes,
and anemia) threaten the well-being of patient [3,12] and the
injection is painful and may result in a scar that can lead to
mental and emotional problems, particularly for women and
children [13]. Therefore, the World Health Organization has
recommended that basic research be conducted regarding
CL [14].
In addition, epidemiological data are needed to establish
effective control strategies in Iran. Using this information, we
can integrate leishmaniasis surveillance into existing health
programs, control outbreaks, investigate vector and reservoir
ﬂuctuations, inform decision makers of high-risk populations,
and improve treatment strategies. However, few studies have
been conducted to examine CL. Therefore, in light of this gap,
this study aimed to assess the epidemic aspects of CL in Iran
over a three-year period.
2. Materials and methods
This study was conducted between 2011 and 2013. Data
regarding age, gender, occupation, residence, nationality, travel
to endemic areas, the number of lesions and lesion sites, the type
of disease, smear results, treatment type, and related complica-
tions were recorded using speciﬁc forms.
These forms were based on the CL control protocol out-
lined by the Center for Disease Control Department ofMinistry of Health and were available for all health centers and
the Academic Reference Laboratory. The importance of stan-
dardized CL identiﬁcation methods and active care systems in
endemic and non-endemic areas in Iran has led to the estab-
lishment of laboratory diagnosis networks. All members of the
society have access to this network. The laboratory network is
divided into three levels: the local level (laboratories at health
centers), the middle level (the Academic Reference Labora-
tory), and the national level (the National Reference Labora-
tory). Most experiments are conducted in the Academic
Reference Laboratory and laboratories at health centers in 31
Iranian provinces.
The working process is as follows: 1. Sample, smear, and ﬁx
suspicious skin lesion samples; 2. Culture the samples using a
Novy-MacNeal-Nicolle medium as a complementary method; 3.
Record the results of the lesion biopsy using speciﬁc forms on
computers; 4. Send the recorded information in separate ﬁles to
the National Reference Laboratory (Contagious Disease Man-
agement Center of the Ministry of Health); 5. Record the in-
formation in Excel at the Contagious Disease Management
Center and analyze the data.
3. Results
During the three-year study period, 56546 patients (56.4%
male, 43.6% female) were diagnosed with CL. The highest
incidence was reported in 2011 (27.5 per 100000) (Table 1).
Urban areas had a higher rate of infection (53.0%) than rural
areas (45.9%). The frequency of CL among Iranian, Afghans,
and patients from other nationalities was 95.7%, 4.1%, and
0.2%, respectively. In addition, 36.0% of the patients had trav-
eled to a known endemic area during the last year.
The most frequent job reported among patients was house-
wife (20.7%) followed by student (17.1%) (Table 2). In addition,
only 7125 cases (12.6%) concerned all family members,
simultaneously (i.e., all members contracted CL at the same
time). The data of Table 3 have been used to calculate the age
speciﬁc incidence rate.
When stratiﬁed by age speciﬁc incidence rate, the highest rate
was observed in 0–4 and 5–9 age groups, respectively (Table 4).
Table 3
Total population data by sex and age group in Iran in each year.
Age group (year) 2011 2012 2013
Male Female Male Female Male Female
0–4 3098103 2946627 3252000 3100000 3316000 3166000
5–9 2795139 2659332 2968000 2824000 3032000 2885000
10–14 2792839 2694169 2856000 2746000 2843000 2725000
15–24 7335585 7289838 7262000 7167000 6966000 6851000
25–34 7709183 7645134 8105000 8031000 8297000 8246000
35–44 5231124 5061888 8458000 5304000 5179000 5473000
45–54 3721653 3714425 3914000 3880000 4036000 3997000
55–64 2173176 2311936 2349000 2466000 2497000 2601000
> 65 2134369 2147154 2122000 2185000 2112000 2223000
Table 4
Age speciﬁc incidence rate per 100000 population. %.
Age group (year) 2011 2012 2013
0–4 43.8 33.6 35.8
5–9 41.3 34.3 32.5
10–14 29.2 26.1 23.9
15–24 31.4 26.3 24.3
25–34 24.5 22.0 18.8
35–44 21.5 21.5 17.1
45–54 22.3 22.0 17.4
55–64 23.4 21.8 18.3
> 65 20.6 19.4 16.5
Total 28.1 24.8 22.0
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had been reported in Fars and Razavi Khorasan Provinces
(Table 5).
Results showed that among the total sample, 35.9% of cases
responded to the treatment and 38.6% of cases were recovering.Table 5
The number of CL cases according to province and age groups between 201
Province
0–4 5–9 10–14 15–2
Razavi Khorasan 1195 1543 1243 260
Fars 1841 1243 849 226
Isfahan 1134 845 634 231
Kerman 416 785 506 70
Khuzestan 689 561 329 84
Ilam 365 188 118 45
Golestan 439 260 146 43
Northern Khorasan 225 147 97 25
Sistan and Balouchestan 277 111 86 36
Yazd 49 85 75 22
Qom 65 69 62 20
Tehran 66 75 52 16
Semnan 47 61 54 17
Bushehr 78 51 35 8
Kermanshah 19 19 11 6
Hormozgan 59 46 21 5
Lorestan 16 15 14 6
Chaharmahal and Bakhtiari 3 4 5 9
South Khorasan 23 17 19 7
Hamadan 2 6 3 6
Kohgiluyeh and Boyer-Ahmad 33 13 16 4
Mazandaran 4 3 10 4
Markazi 7 2 5 4
Alborz 6 13 4 2
West Azerbaijan 0 1 0 4A small number of patients (1.5%) refused to continue treatment,
3% relapsed after treatment, and 0.9% experienced side effects.
The most common lesion site was the hands (35.2%) while the
face was the least common (13.2%). In this study, 26020
(35.0%) patients reported one lesion, 12535 (6.9%) reported two
lesions, and 17014 (22.9%) reported three lesions.
The results of this study showed that Leishmania major
(L. major) was more prevalent than the Leishmania tropica
(L. tropica). Furthermore, the wet form of the lesions was the
most prevalent (43.7%) while the sporotrichoid form was the
least (0.1%). Smear results were positive in 42871 cases
(75.8%) (Table 6).
The results also indicated that the cases of the disease varied
by month. For example, the highest case was found in
September (20.5%), followed by August (17.6%), and then
October (15.8%) (Figure 2).
The highest incidence of CL was reported in Ilam followed
by Fars and Razavi Khorasan Province (Table 7, Figure 3).1 and 2013.
Age (year) Total
4 25–34 35–44 45–54 55–64 > 65
9 2513 1663 1216 775 622 13379
8 2568 1772 1313 830 672 13356
6 1716 780 610 398 352 8785
0 697 469 397 266 199 4435
2 525 284 179 107 99 3615
1 429 233 128 74 41 2027
0 276 165 135 76 33 1960
3 227 129 110 63 35 1286
2 155 53 45 32 23 1144
0 189 164 126 89 72 1069
9 241 147 111 60 48 1012
3 140 136 98 60 58 848
2 170 88 58 57 79 786
4 60 44 16 9 8 385
9 69 57 53 29 29 355
5 46 28 12 10 9 286
9 62 36 34 15 9 270
0 75 30 19 9 7 242
4 37 22 16 12 6 226
1 68 31 24 11 3 209
3 29 24 13 15 9 195
7 33 13 19 11 10 150
8 22 12 7 8 4 115
8 22 16 16 7 3 115
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Figure 2. Monthly distribution (%) of CL among 56546 Iranian patients.
Table 7
Incidence rate of CL cases by province per 100000 population in Iran
between 2011 and 2013.
Province Total number 2011 2012 2013
Ilam 2026 159.61 98.70 102.64
Fars 13359 115.02 86.10 86.77
Razavi Khorasan 13383 74.20 81.90 64.09
Isfahan 8786 58.01 59.85 60.30
Semnan 787 65.90 28.75 28.73
Kerman 4437 57.31 48.88 42.53
Northern Khorasan 1286 52.20 43.54 50.68
Golestan 1960 38.39 37.17 32.90
Khuzestan 3615 37.39 21.75 19.83
Yazd 1069 36.68 35.45 27.53
Qom 1012 33.17 34.58 18.78
Sistan and Balouchestan 1144 17.99 12.73 13.61
Bushehr 385 14.52 10.89 11.05
South Khorasan 226 13.13 12.58 7.33
Kohgiluyeh and Boyer-Ahmad 195 11.99 9.49 7.78
Chaharmahal and Bakhtiari 242 7.48 11.85 7.44
Kermanshah 355 6.48 8.22 3.47
Hormozgan 286 6.27 5.08 6.39
Lorestan 270 4.16 5.16 5.94
Hamadan 209 3.75 5.09 2.98
Markazi 115 2.55 4.00 1.53
Tehran 848 1.08 3.85 1.93
West Azerbaijan 90 1.07 1.47 0.77
Mazandaran 150 1.53 1.80 1.50
Alborz 115 1.12 2.45 1.08
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Figure 3. Leishmaniasis incidence rate per 100000 population between
2011 and 2013.
Table 6
Clinical indicators of CL in the samples.
Clinical
characteristics
n (%)
Number of lesions 1 26020 (35.0)
2 12535 (6.9)
 3 17014 (22.9)
Type of treatment Cryotherapy + local glucantime 7514 (13.3)
Local glucantime 18684 (33.0)
Systemic glucantime 18091 (32.0)
Cryotherapy 4878 (8.6)
Smear result Positive 42871 (75.8)
Negative 324 (0.6)
Lesion location Hands 26145 (35.2)
Feet 17069 (23.0)
Face 9807 (13.2)
Clinical form of the
lesion
Dry 24493 (43.3)
Sporotrichoid 71 (0.1)
Lupoid 98 (0.2)
Type of CL L. tropica 18900 (33.4)
L. major 28388 (50.2)
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Although the incidence of leishmaniasis declined between
2011 and 2013, the results of this study conﬁrmed that the
disease is endemic in Iran and that it infects many people each
year. In addition, although the incidence of the disease is
declining, CL is still a public health concern and disease control
protocols need to be established. The results of this study found
that the highest incidence of CL has happened in 0–4 and 5–9
age groups, respectively, which support previous research. For
example, studies conducted by Khosravi et al., Khajedaluee
et al., Fakoorziba et al., and Nateghi Rostami et al. found similar
results in several different provinces throughout Iran [1,12,15,16].
This may be because children of this age play outdoors and are,
Faezeh Norouzinezhad et al./Asian Pac J Trop Biomed 2016; 6(7): 614–619618thus, more likely to be exposed to the source of infection than
older children or adults. Similar ﬁndings have been found in
other studies, supporting this explanation [1].
The results also showed a highest case of CL in men than in
women. These results are consistent with other studies [15,16] and
may be explained by several reasons. For example, the number
of men in the workforce is higher than the number of women
and men are more likely to migrate seasonally for factory or
farm work. In addition, men cover their bodies less than
women increasing the likelihood of contact with sand ﬂies in
the evening [17]. Furthermore, the highest case was found
among people living in urban areas. Therefore, it is important
that health promotion programs should target people in urban
areas, increase CL knowledge, and provide individualized
protection plans [18].
In addition, the highest disease case was observed in
September, October, and August, respectively. Results are
consistent with those in a study conducted by Niloufarzadeh
et al. [19].
The highest case was found in Iranians. This supports results
found in previous studies. For example, Karami et al. also
suggested that 81.2% of patients were Iranian followed by Af-
ghans and other nationalities [20]. Similar studies have also
found that the Iranian population has the highest prevalence of
CL [16].
In this study, most patients reported having one lesion
(22.9%) or three or more lesions. Previous studies have also
found that patients reported more than one lesion [19,21,22].
The results of this study also showed that the lesions were
most commonly found on the hands and feet, a ﬁnding that is
consistent with other studies. Since CL causes numerous com-
plications (e.g., scars, aesthetic problems, and mental health is-
sues), control and prevention of this disease is important [19,23].
Although a small percentage of patients (3%) in the study
relapsed after treatment or discontinued treatment, given that
leishmaniasis is endemic in Iran, relapses and treatment failures
should be considered [24].
The results showed that a signiﬁcant number of patients
improved after treatment and were recovering. This reﬂects an
increasing awareness of early symptoms and available treatment
options as well as the success of skilled health personnel in early
detection and early treatment of this disease [12].
The two most common species to cause CL are L. tropica and
L. major. Based on clinical presentations, the results showed that
most patients were infected with L. major while 33.4% of pa-
tients were infected with L. tropica [25].
L. major is endemic in Iran. It is very common in many rural
areas, particularly in the northeastern plains near the Russian
border, in the northern part of Isfahan Province, and in the center
of the country. However, this species has recently spread to the
south and to Fars Province in Southwestern Iran. The endemic
rate is so high that almost 80% of the rural population contracts
the disease before the age of 10 and practically all non-immune
newcomers become infected [26]. CL caused by L. tropica is
found in Tehran as well as in some other large or medium-
sized cities and their suburbs. In addition, increases in the
population size, unplanned urban developments, and an increase
in the sand ﬂy population have caused previous outbreaks [27].
For example, over the 5 years after the 2003 earthquake, there
was an eight-fold increase in the number of cases in the city
of Bam. Furthermore, recent outbreaks in Bam caused 2884
cases in 2007, 3442 in 2008, and 1372 in 2009 [7].In this study, the highest prevalence of CL was reported in
the provinces of Ilam, Fars and, Khorasan Razavi respectively.
A study conducted by Fakoorziba et al. also found that the
highest prevalence was in Razavi Khorasan Province followed
by Yazd, Bushehr, Fars, Khuzestan, Ilam and Isfahan [15].
Furthermore, in 2007, the highest CL outbreak rates were
found in Khorasan, Fars, Isfahan, Khuzestan, and Kerman
Provinces while Ilam, Bushehr, and Yazd had the highest
incidence of cases in recent years.
The highest incidence of CL was reported in provinces such
as Yazd, Bushehr, Khorasan, Fars, Ilam, Khuzestan, and Isfahan
where the average was 166 cases per 100000 people. In contrast,
provinces in Western and Northwestern Iran have reported the
lowest incidence of CL (less than 10/1000) [28].
Therefore, further studies are required to identify the vectors,
reservoirs, and species of this disease as well as to design
appropriate control strategies.
In order to prevent leishmaniasis, health education concern-
ing this disease is critical and protection facilities are recom-
mended in endemic areas.
Although the case of CL in urban areas is higher than rural
areas, the rates are similar. Therefore, health education, rodent
control, environmental reform, and proper disposal of garbage
and sewage are important control measures. Using insecticide-
treated mosquito nets may also be effective for preventing this
disease and information regarding these nets should be provided
through public media. In addition, programs aimed at in-
dividuals as well as groups are of high importance.
Given the high incidence in children and housewives, tar-
geted training may help increase health literacy and prevent the
disease among these groups.
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